<DOC>
	<DOC>NCT01582230</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of vildagliptin 50mg bid add-on therapy to improve overall glycemic control in patients with type 2 diabetes mellitus inadequately controlled on insulin with or without metformin treatment.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients with confirmed diagnosis of Type2 diabetes mellitus (T2DM) by standard criteria Cpeptide &gt;0.6 ng/ml (&gt;0.20 nmol/L). HbA1c ≥7.5 to ≤11% at Visit 1 Treatment with stable, once or twice daily doses (maximum dose of &lt; 1 unit/kg/day) of basal (longacting, intermediateacting) insulin alone or premixed insulin for at least 12 weeks prior to Visit 1. Stable is defined as ±10% of the Visit 1 dose during the previous 12 weeks Patients receiving metformin must be on a stable dose of metformin (at least 1500 mg daily or a maximally tolerated dose) for at least 12 weeks prior to Visit 1 Body Mass Index (BMI) ≥20 to ≤40 kg/m2 at Visit Patients fulfilling any of the following criteria are not eligible for participation in the study Fasting plasma glucose (FPG) ≥240 mg/dl (13.3 mmol/L) at Visit 1 Pregnant or lactating women Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months Current diagnosis of congestive heart failure (NYHA III or IV). Myocardial infarction (MI) within the past 6 months Liver disease such as cirrhosis or chronic active hepatitis Other protocol defined inclusion/excusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Vildagliptin</keyword>
</DOC>